Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09
Kwon JS et al. – BRCA testing of women with ovarian cancer based on personal/family history of cancer or Ashkenazi Jewish ancestry is a cost-effective strategy to prevent future breast and ovarian cancers among FDRs. More inclusive testing strategies prevent additional cancer cases but at significant cost.
Methods- Developed a Markov Monte Carlo simulation model to compare four criteria for BRCA testing in women with ovarian cancer: no testing (reference); only if personal history of breast cancer, family history of breast/ovarian cancer, or Ashkenazi Jewish ancestry; only if invasive serous cancer; any invasive nonmucinous epithelial cancer
- Net health benefit was life expectancy for FDRs and primary outcome was incremental cost-effectiveness ratio (ICER)
- Model estimated number of future breast and ovarian cancer cases in FDRs
- BRCA testing based on personal/family history and ancestry could prevent future cases in FDRs with an ICER of $32,018 per year of life (LY) gained compared with reference strategy
- BRCA testing based on serous or any nonmucinous epithelial ovarian cancer could prevent more cancer cases, but at ICERs of $128,465 and $148,363 per LY gained, respectively
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells
Oncogene, 11/25/09
Adenosine A1 receptor, a target and regulator of estrogen receptor action, mediates the proliferative effects of estradiol in breast cancer
Oncogene, 11/25/09
Extrapulmonary small cell carcinoma in breast and prostate
Clinical and Translational Oncology, 11/25/09
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis
Oncogene, 11/25/09
Paracentesis in Ovarian Cancer: A Study of the Physiology during Free Drainage of Ascites
Journal of Palliative Medicine, 11/25/09
How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


